Meeting
2023 ASCO Genitourinary Cancers Symposium
Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG.
Authors
Karim Chamie
UCLA Dept of Urology, Los Angeles, CA
Karim Chamie , Sam S. Chang , Eugene V. Kramolowsky , Mark L. Gonzalgo , Stanislav Lechpammer , Sandeep K. Reddy , Patrick Soon-Shiong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT03022825
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 495)
DOI
10.1200/JCO.2023.41.6_suppl.495
Abstract #
495
Poster Bd #
J17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I/II randomized clinical trial of in-clinic acupuncture prior to BCG in patients with high-risk non-muscle invasive bladder cancer.
First Author: Sarah P. Psutka
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
First Author: Franklin D Gaylis
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 1, open-label trial to evaluate feasibility and safety of intramural injection of belzupacap sarotalocan (AU-011) in non-muscle–invasive bladder cancer (NMIBC).
First Author: Seth P. Lerner
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among patients with non-muscle invasive bladder cancer (NMIBC) treated with intravesical Bacillus Calmette-Guerin (BCG).
First Author: Neela Kumar